PETER ANTHONY CAMPOCHIARO, M.D.
Medical Practice at Wolfe St, Baltimore, MD
License number
Maryland D29624
Category
Medical Practice
Type
Ophthalmology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-5080
Personal information
See more information about PETER ANTHONY CAMPOCHIARO at radaris.comName
Address
Phone
920 W Lake Ave, Baltimore, MD 21210
Towson, MD
920 Lake Ave, Baltimore, MD 21210
920 Lake Ave, Baltimore, MD 21210
926 Lake Ave, Baltimore, MD 21210
Professional information
Non-Linear Multiblock Copolymer-Drug Conjugates For The Delivery Of Active Agents
US Patent:
2013027, Oct 17, 2013
Filed:
Mar 12, 2013
Appl. No.:
13/797531
Inventors:
Peter A. Campochiaro - Baltimore MD, US
Justin Scot Hanes - Baltimore MD, US
Justin Scot Hanes - Baltimore MD, US
International Classification:
A61K 47/48
US Classification:
424 7817, 525 542
Abstract:
Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.
Selective Induction Of Apoptosis To Treat Ocular Disease
US Patent:
2006014, Jul 6, 2006
Filed:
Mar 16, 2006
Appl. No.:
11/377857
Inventors:
Peter Campochiaro - Baltimore MD, US
Assignee:
Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
A61K 48/00
US Classification:
424093200, 514044000
Abstract:
The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial cells associated with neovascularization of the choroid such that choroidal neovascularization is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating ocular neovascularization, wherein the method comprises directly administering to the eye a nucleic acid sequence encoding a therapeutic factor to promote apoptosis of endothelial cells associated with neovascularization, such that the nucleic acid is expressed thereby producing the therapeutic factor to treat ocular neovascularization prophylactically or therapeutically.
Compositions And Methods For The Treatment Of Ocular Oxidative Stress And Retinitis Pigmentosa
US Patent:
2012010, May 3, 2012
Filed:
Jun 30, 2009
Appl. No.:
13/002243
Inventors:
Peter A. Campochiaro - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 31/7088, A61P 27/02, A61P 9/10, A61P 39/06, A61P 9/04, A61P 25/28, A61P 3/10, A61P 9/00, C12N 15/63, A61P 25/16
US Classification:
514 44 R, 4353201
Abstract:
Oxidative damage contributes to cone cell death in retinitis pigmentosa and death of rods, cones, and retinal pigmented epithelial (RPE) cells in ocular oxidative stress related diseases including age-related macular degeneration and retinitis pigmentosa. Oral antioxidants may provide modest benefits, but more efficient ways of preventing oxidative damage are needed. Compositions and methods are provided herein for the prevention, amelioration, and/or treatment of early or late stage ocular disease by increasing the expression or activity of one or more peroxidases in cells of the eye, particularly retinal cells, and further optionally increasing the expression or activity of one or more superoxide dismuatases in the same cells.
Methods Of Treatment Of Ocular Neovascularization
US Patent:
2002000, Jan 17, 2002
Filed:
Jun 18, 1998
Appl. No.:
09/100790
Inventors:
PETER A. CAMPOCHIARO - BALTIMORE MD, US
International Classification:
C07C229/00, A61K031/075, C07D233/54, A61K031/47, C07D233/60, C07D233/90
US Classification:
514/715000, 514/716000, 514/717000, 560/147000, 560/155000, 548/338100
Abstract:
The present invention includes methods for treatment and prophylaxis of eye disorders and injuries, particularly treatment and prophylaxis of ocular neovascularization and disorders, especially a vasculopathy that affects retinal or chorodial vessels. The methods of the invention in general comprise administration of a therapeutically effective amount of a compound that inhibits farnesyl-protein transferase to a subject suffering from or susceptible to ocular neovascularization or associated disorder.
Method For Treating Ocular Neovascularization
US Patent:
2013016, Jun 27, 2013
Filed:
Dec 17, 2012
Appl. No.:
13/716925
Inventors:
Romulus Kimbro BRAZZELL - Morrisville NC, US
Peter Anthony CAMPOCHIARO - Baltimore MD, US
Katharine Hilary DIXON - Olney MD, US
Michael KALEKO - Rockville MD, US
Tianci LUO - Clarksville MD, US
Peter Anthony CAMPOCHIARO - Baltimore MD, US
Katharine Hilary DIXON - Olney MD, US
Michael KALEKO - Rockville MD, US
Tianci LUO - Clarksville MD, US
Assignee:
NOVARTIS AG - Basel
International Classification:
C07K 14/78
US Classification:
514 44 R
Abstract:
Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.
Method For Decreasing Capillary Permeability In The Retina
US Patent:
2005020, Sep 22, 2005
Filed:
Apr 29, 2003
Appl. No.:
10/512505
Inventors:
Romulus Brazzell - Alpharetta GA, US
Kenneth Green - Alpharetta GA, US
Frances Kane - Cumming GA, US
Peter Campochiaro - Baltimore MD, US
Kenneth Green - Alpharetta GA, US
Frances Kane - Cumming GA, US
Peter Campochiaro - Baltimore MD, US
International Classification:
A61K031/502
US Classification:
514248000
Abstract:
Disclosed herein are methods for decreasing or attenuating an increase in capillary permeability in the retina in a subject in need of such treatment, comprising administering a composition comprising an amount of a phthalazine derivative or a salt thereof to a subject suffering from excessive or pathological capillary permeability in the retina, the amount of phthalazine derivative or salt thereof being effective to decrease the permeability of capillaries in the retina of the subject, in particular where the subject is suffering from macular edema.
Compositions And Methods Related To Mirna Modulation Of Neovascularization Or Angiogenesis
US Patent:
2013006, Mar 14, 2013
Filed:
Sep 4, 2012
Appl. No.:
13/602933
Inventors:
Jikui Shen - Dundlak MD, US
Kevin Kelnar - Kyle TX, US
Jeffrey Shelton - Buda TX, US
David Brown - Austin TX, US
Peter Campochiaro - Baltimore MD, US
Kevin Kelnar - Kyle TX, US
Jeffrey Shelton - Buda TX, US
David Brown - Austin TX, US
Peter Campochiaro - Baltimore MD, US
International Classification:
A61K 31/7105, C40B 40/06, C40B 30/04, C12M 1/34, A61P 7/00, C12Q 1/68
US Classification:
514 44 R, 435 612, 435 611, 506 9, 4352872, 506 16
Abstract:
The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the test results to diagnose and/or predict an optimal treatment regimen for the patient. Compositions described in the invention include nucleic acids that function as miRNAs or miRNA inhibitors that can be introduced to a patient to reduce or increase vascularization as needed.
Method For Treating Ocular Neovascularization
US Patent:
8338384, Dec 25, 2012
Filed:
May 23, 2010
Appl. No.:
12/785461
Inventors:
Romulus Kimbro Brazzell - Morrisville NC, US
Peter Anthony Campochiaro - Baltimore MD, US
Katharine Hilary Dixon - Olney MD, US
Michael Kaleko - Rockville MD, US
Tianci Luo - Clarksville MD, US
Peter Anthony Campochiaro - Baltimore MD, US
Katharine Hilary Dixon - Olney MD, US
Michael Kaleko - Rockville MD, US
Tianci Luo - Clarksville MD, US
Assignee:
Novartis AG - Basel
International Classification:
C12N 15/11
US Classification:
514 44A
Abstract:
Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.
Method For Treating Ocular Neovascular Diseases
US Patent:
6271233, Aug 7, 2001
Filed:
Aug 10, 1999
Appl. No.:
9/371746
Inventors:
Romulus Kimbro Brazzell - Alpharetta GA
Jeanette Marjorie Wood - Biel Benken, CH
Peter Anthony Campochiaro - Baltimore MD
Frances Elizabeth Kane - Gainesville GA
Jeanette Marjorie Wood - Biel Benken, CH
Peter Anthony Campochiaro - Baltimore MD
Frances Elizabeth Kane - Gainesville GA
Assignee:
CIBA Vision Corporation - Deluth GA
International Classification:
A01N 4358
US Classification:
514249
Abstract:
The invention relates to the use of certain phthalazines in the preparation of medicaments for the treatment of ocular neovascularization.
Ocular Therapy
US Patent:
7268137, Sep 11, 2007
Filed:
Nov 7, 2003
Appl. No.:
10/704297
Inventors:
Peter A. Campochiaro - Baltimore MD, US
International Classification:
A61K 31/50
US Classification:
514249, 514912
Abstract:
A method for treating a subject suffering from epiretinal membrane formation or retinal detachment due to epiretinal membrane formation is disclosed. The method comprises administering a compound of the formula:.